Liyan Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Liyan Li has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Qiang Li
The Department of Laboratory Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
3 shared publicationsWangjie Jin
Technology Center of Prenatal Diagnosis and Genetic Diseases Diagnosis, Department of Gynecology and Obstetrics, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
3 shared publicationsYihong Li
Technology Center of Prenatal Diagnosis and Genetic Diseases Diagnosis, Department of Gynecology and Obstetrics, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
3 shared publicationsDongmei Fan
Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou 510515, China
2 shared publicationsFenxia Li
Technology Center of Prenatal Diagnosis and Genetic Diseases Diagnosis, Department of Gynecology and Obstetrics, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
2 shared publicationsLimin Huang
Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou 510515, China
2 shared publications
Latest Publications
- 1 June 2021
- Published by Elsevier in Thrombosis Research
- Vol. 202, 8-13
The spectrum of FVIII gene variants detected by next generation sequencing in 236 Chinese non-inversion hemophilia A pedigrees
- 1 June 2021
- Published by Elsevier in Thrombosis Research
- Vol. 202, 8-13
The spectrum of FVIII gene variants detected by next generation sequencing in 236 Chinese non-inversion hemophilia A pedigrees
- Open Access
- 1 May 2020
- Published by Wiley in British Journal of Haematology
- Vol. 189 (4) , E166-E168
Target capture next-generation sequencing in non-inversion haemophilia: an alternative approach
- 1 May 2020
- Published by Wiley in British Journal of Haematology
- Vol. 189 (4) , E166-E168
Open AccessTarget capture next-generation sequencing in non-inversion haemophilia: an alternative approach
- 4 July 2018
- Published by Taylor & Francis in Hemoglobin
- Vol. 42 (4) , 278-280
A Rare Hb H Hydrops Fetalis Syndrome Caused by the – –SEA Deletion in Combination with the Rare Hb Hirosaki Mutation in a Chinese Patient
Despite the milder clinical severity of Hb H patients compared with those of Hb Bart’s hydrops fetalis or patients with β-thalassemia major (β-TM), a few cases of Hb H hydrops fetalis syndrome have been reported so far. Here, we describe, for the first time in the Chinese population, one case of a neonate with Hb H hydrops fetalis syndrome caused by the – –SEA (Southeast Asian) deletion in combination with the Hb Hirosaki (HBA2: c.132C>G, p.Phe43Leu) mutation. Our study highlights the importance of continuous fetal monitoring using ultrasonography and blood screening studies of fetuses. Appropriate genetic counseling and comprehensive clinical follow-up should be performed on a pregnant woman who carried an α0-thalassemia (α0-thal) deletion and had a Hb H or Hb Bart’s hydrops fetalis offspring, especially if the woman’s partner also carried a hemoglobinopathy.
- 4 July 2018
- Published by Taylor & Francis in Hemoglobin
- Vol. 42 (4) , 278-280
A Rare Hb H Hydrops Fetalis Syndrome Caused by the – –SEA Deletion in Combination with the Rare Hb Hirosaki Mutation in a Chinese Patient
Despite the milder clinical severity of Hb H patients compared with those of Hb Bart’s hydrops fetalis or patients with β-thalassemia major (β-TM), a few cases of Hb H hydrops fetalis syndrome have been reported so far. Here, we describe, for the first time in the Chinese population, one case of a neonate with Hb H hydrops fetalis syndrome caused by the – –SEA (Southeast Asian) deletion in combination with the Hb Hirosaki (HBA2: c.132C>G, p.Phe43Leu) mutation. Our study highlights the importance of continuous fetal monitoring using ultrasonography and blood screening studies of fetuses. Appropriate genetic counseling and comprehensive clinical follow-up should be performed on a pregnant woman who carried an α0-thalassemia (α0-thal) deletion and had a Hb H or Hb Bart’s hydrops fetalis offspring, especially if the woman’s partner also carried a hemoglobinopathy.
- Open Access
- 25 February 2010
- Published by Springer Nature in BMC Medical Genetics
- Vol. 11 (1) , 31
The molecular basis of beta-thalassemia intermedia in southern China: genotypic heterogeneity and phenotypic diversity
Background: The clinical syndrome of thalassemia intermedia (TI) results from the β-globin genotypes in combination with factors to produce fetal haemoglobin (HbF) and/or co-inheritance of α-thalassemia. However, very little is currently known of the molecular basis of Chinese TI patients. Methods: We systematically analyzed and characterized β-globin genotypes, α-thalassemia determinants, and known primary genetic modifiers linked to the production of HbF and the aggravation of α/β imbalance in 117 Chinese TI patients. Genotype-phenotype correlations were analyzed based on retrospective clinical observations. Results: A total of 117 TI patients were divided into two major groups, namely heterozygous β-thalassemia (n = 20) in which 14 were characterized as having a mild TI with the Hb levels of 68-95 g/L except for five co-inherited αααanti-3.7 triplication and one carried a dominant mutation; and β-thalassemia homozygotes or compound heterozygotes for β-thalassemia and other β-globin defects in which the β+-thalassemia mutation was the most common (49/97), hemoglobin E (HbE) variants was second (27/97), and deletional hereditary persistence of fetal hemoglobin (HPFH) or δβ-thalassemia was third (11/97). Two novel mutations, Term CD+32(A→C) and Cap+39(C→T), have been detected. Conclusions: Chinese TI patients showed considerable heterogeneity, both phenotypically and genotypically. The clinical outcomes of our TI patients were mostly explained by the genotypes linked to the β- and α-globin gene cluster. However, for a group of 14 patients (13 β0/βN and 1 β+/βN) with known heterozygous mutations of β-thalassemia and three with homozygous β-thalassemia (β0/β0), the existence of other causative genetic determinants is remaining to be molecularly defined.
- 25 February 2010
- Published by Springer Nature in BMC Medical Genetics
- Vol. 11 (1) , 31
Open AccessThe molecular basis of beta-thalassemia intermedia in southern China: genotypic heterogeneity and phenotypic diversity
Background: The clinical syndrome of thalassemia intermedia (TI) results from the β-globin genotypes in combination with factors to produce fetal haemoglobin (HbF) and/or co-inheritance of α-thalassemia. However, very little is currently known of the molecular basis of Chinese TI patients. Methods: We systematically analyzed and characterized β-globin genotypes, α-thalassemia determinants, and known primary genetic modifiers linked to the production of HbF and the aggravation of α/β imbalance in 117 Chinese TI patients. Genotype-phenotype correlations were analyzed based on retrospective clinical observations. Results: A total of 117 TI patients were divided into two major groups, namely heterozygous β-thalassemia (n = 20) in which 14 were characterized as having a mild TI with the Hb levels of 68-95 g/L except for five co-inherited αααanti-3.7 triplication and one carried a dominant mutation; and β-thalassemia homozygotes or compound heterozygotes for β-thalassemia and other β-globin defects in which the β+-thalassemia mutation was the most common (49/97), hemoglobin E (HbE) variants was second (27/97), and deletional hereditary persistence of fetal hemoglobin (HPFH) or δβ-thalassemia was third (11/97). Two novel mutations, Term CD+32(A→C) and Cap+39(C→T), have been detected. Conclusions: Chinese TI patients showed considerable heterogeneity, both phenotypically and genotypically. The clinical outcomes of our TI patients were mostly explained by the genotypes linked to the β- and α-globin gene cluster. However, for a group of 14 patients (13 β0/βN and 1 β+/βN) with known heterozygous mutations of β-thalassemia and three with homozygous β-thalassemia (β0/β0), the existence of other causative genetic determinants is remaining to be molecularly defined.